Labquality EQA program 2024

Labquality proudly presents the new external quality assessment program for 2024. The new product catalogue introduces 5 new EQA schemes from Labquality and an additional 6 new schemes from Equalis. The program includes more than 180 clinically relevant external quality assessment schemes and fully complies with ISO 15189 standard requirements.

Labquality provides clinically relevant EQA programmes to support continuous quality improvements for the benefit of patients. Labquality’s external quality assessment program is aimed at medical laboratories and point-of-care testing sites.

New schemes and products

• 2707 Maternal serum screening
• 8205 Pipette control
• 5254 Mycoplasma genitalium, drug resistance, nucleic acid detection
• 5253 Helicobacter pylori, nucleic acid detection
• 5683 Mpox (Monkeypox virus), nucleic acid detection
• 8850 DNA sequencing (EQUALIS)
• 8851 Quantification of ABO antibodies (EQUALIS)
• 8852 Titration of erythrocyte antibodies (EQUALIS)
• 8853 Iohexol (EQUALIS)
• 8854 Phosphatidyl ethanol in blood (EQUALIS)
• 8855 Alcohol biomarkers in urine (EQUALIS)

Information about the contents and schedules of pilot schemes will be announced later. Pilot schemes are EQA schemes under our product development.

More information

Sales and customer service
info@labquality.fi
+358 9 85668200